24502-78-1 Usage
Description
Acetylshikonin, a naturally occurring biologically active compound, is derived from the roots of Lithospermum erythrorhizoma. It exhibits potent anti-cancer and anti-inflammatory properties, making it a valuable substance for pharmaceutical and medical applications.
Uses
Used in Pharmaceutical Industry:
Acetylshikonin is used as a therapeutic agent for its anti-cancer properties. It has been found to be effective against various types of cancer, including leukemia, breast, lung, and liver cancer. The compound works by inhibiting the proliferation of cancer cells and inducing apoptosis, leading to the suppression of tumor growth.
Additionally, Acetylshikonin is used as an anti-inflammatory agent due to its ability to reduce inflammation and alleviate pain. It has been shown to modulate inflammatory signaling pathways, making it a potential candidate for the treatment of various inflammatory diseases.
Used in Cosmetic Industry:
Acetylshikonin is also used as an ingredient in the cosmetic industry, where it is valued for its skin-soothing and anti-inflammatory effects. It can be found in products designed to reduce redness, irritation, and inflammation, as well as in formulations aimed at promoting skin healing and regeneration.
Biological Activity
Acetylshikonin is one naphthoquinone derivative isolated from the Lithospermum erythrorhizon, exhibits weak cytotoxicity against human umbilical vein endothelial cells (HUVECs) with IC50 of over 20 microM, exhibits the antiangiogenic and antitumorigenic effects by suppressing proliferation and angiogenic factors.
Acetylshikonin inhibits the generation of NADPH oxidase complex in the activation of respiratory burst of PMNs, but does not directly inhibit the activity of NADPH oxidase already generated.
Certain shikonin derivatives(such as Acetyl shikonin) act as modulators of the Nur77-mediated apoptotic pathway and identify a new shikonin-based lead that targets Nur77 for apoptosis induction.
Acetylshikonin, shikonin, and alkannin have accelerative effect on the proliferation of granulation tissue in rats.
Acetylshikonin isolated from Arnebia euchroma (Royle) Johnst cell suspension cultures exhibits specific in vivo and in vitro antitumor effects.
Acetylshikonin has inhibitory effect on the edematous response is due neither to the release of steroid hormones from the adrenal gland nor to the glucocorticoid activity, but probably partly to the suppression of mast cell degranulation and partly to protection of the vasculature from mediator challenge.
Acetylshikonin induces apoptosis of hepatitis B virus X protein-expressing human hepatocellular carcinoma cells via endoplasmic reticulum stress.
Check Digit Verification of cas no
The CAS Registry Mumber 24502-78-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,5,0 and 2 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 24502-78:
(7*2)+(6*4)+(5*5)+(4*0)+(3*2)+(2*7)+(1*8)=91
91 % 10 = 1
So 24502-78-1 is a valid CAS Registry Number.
InChI:InChI=1/C18H18O6/c1-9(2)4-7-15(24-10(3)19)11-8-14(22)16-12(20)5-6-13(21)17(16)18(11)23/h4-6,8,15,20-21H,7H2,1-3H3/t15-/m1/s1
24502-78-1Relevant articles and documents
Design and synthesis of fluoroacylshikonin as an anticancer agent
Kong, Wen-Yao,Chen, Xiao-Feng,Shi, Jing,Baloch, Shahla Karim,Qi, Jin-Liang,Zhu, Hai-Liang,Wang, Xiao-Ming,Yang, Yong-Hua
, p. 757 - 762 (2013/11/06)
A series of shikonin derivatives, selectively acylated by various fluorinated carboxylic acids at the side chain of shikonin, were synthesized and their anticancer activity evaluated, in which eight compounds are reported for the first time. Among all the compounds tested, compound S7 showed the most potent anticancer activity against B16-F10 (malignant melanoma cells), MG63 (human osteosarcoma cells), and A549 (lung cancer cells) with IC50 0.39 ± 0.01, 0.72 ± 0.04 and 0.58 ± 0.02 μmol/L. Docking simulation of compound S7 was carried out to position S7 into a tubulin active site to determine the probable binding conformation. All the results suggested that compound S7 may be a potential anticancer agent. Chirality 25:757-762, 2013. 2013 Wiley Periodicals, Inc. Copyright
Acylshikonin analogues: Synthesis and inhibition of DNA topoisomerase-I
Ahn,Baik,Kweon,Lim,Hwang
, p. 1044 - 1047 (2007/10/02)
Compounds bearing an acyl group of a various size at 1'-OH of shikonin were synthesized as acyl analogues of shikonin, which was isolated from the root of Lithospermum erythrorhizon, and evaluated for inhibitory effect on topoisomerase-I activity. A selec